INVESTOR PRESENTATION - VIFOR PHARMA

Page created by Sidney Green
 
CONTINUE READING
INVESTOR PRESENTATION - VIFOR PHARMA
PRESENTATION

               VIFOR PHARMA
               INVESTOR PRESENTATION

               January 2019
INVESTOR PRESENTATION - VIFOR PHARMA
VIFOR PHARMA
OUR VISION

                            Global leader
                   in iron deficiency, nephrology
                     and cardio-renal therapies.

© Vifor Pharma   January 2019                       2
INVESTOR PRESENTATION - VIFOR PHARMA
EXPERIENCED LEADERSHIP TEAM
PROVEN TRACK RECORD

            ETIENNE JORNOD         STEFAN SCHULZE                COLIN BOND
        EXECUTIVE CHAIRMAN      PRESIDENT OF THE EXECUTIVE   CHIEF FINANCIAL OFFICER
    OF THE BOARD OF DIRECTORS        COMMITTEE & COO

© Vifor Pharma   January 2019                                                          3
INVESTOR PRESENTATION - VIFOR PHARMA
PROVEN TRACK RECORD
CORPORATE TIMELINE AND STRATEGY
                                                                                                                        2020
                                                                                     2015
                                     2010
2000                                                                                    BECOMING GLOBAL LEADER
                                                                                        IN NEPHROLOGY AND ENTERING
                                            BECOMING GLOBAL LEADER
                                                                                        CARDIO-RENAL DISEASE AREA
 BUILDING IRON PORTFOLIO                    IN IRON DEFICIENCY AND
 AND INTERNATIONAL EXPANSION                ENTERING INTO NEPHROLOGY                    • 2015: Mircera® license

 • 2000: Venofer® US FDA approval                                                       • 2015: Veltassa® license
                                            • 2010: Creation of VFMCRP                  • 2016: Four licensing deals
 • 2007: Launch of     Ferinject®
                                            • 2013:   Injectafer®   – FDA approval      • 2016: Relypsa acquisition
 • 2008: Acquisition Aspreva
                                            • 2013: Launch of Velphoro®                 • 2017: Galenica Santé IPO
 • 2008: Creation of EU affiliates
 • 2009: Acquisition OM Pharma                                                          • 2017: Vadadustat license
                                                                                        • 2017: Veltassa® EU approval
                                                                                        • 2017: Mircera® license expansion
                                                                                        • 2018: CR845 license

© Vifor Pharma   January 2019                                                                                                4
INVESTOR PRESENTATION - VIFOR PHARMA
LEADING PORTFOLIO IN TARGET THERAPY AREAS

                                                 Iron
                                                           Nephrology                  Cardio-renal
                                              deficiency

   Own
 products

In-licensed                                                     Avacopan1) CCX1401)
                                                           1)
 products
                                                                Vadadustat1) CR8451)

1) Pre-commercial   products

© Vifor Pharma                 January 2019                                                           5
THREE STRATEGIC GROWTH DRIVERS

                    Ferinject®
                    Exploit the potential through market awareness

                    Vifor Fresenius Medical Care Renal Pharma
                    Grow and enhance value

                    Veltassa®
                    Build a blockbuster

© Vifor Pharma   January 2019                                        6
FERINJECT®
A BLOCKBUSTER BY 2020
FERINJECT   ® IN-MARKET
GLOBAL I.V. IRON             Q2 1)2018)
                         SALES
                 MARKET (MAT       (MCHF)
                                       1)                                                                                                                     IN-MARKET SALES1)
                                                                                                                                                              CHF MILLION
• Market totalled CHF 1’698 million, +15% versus prior year period
• Ferinject® growth represented 88% of the total market growth, with +32% versus prior year period                                                                                 850-880
• Global market share of              Ferinject®      in value is 47% (54% in our top 10 markets)
                                                                                                                                                                      692
                                                                                                                                                         535
                                                                                                                                    374
                                                                                                                         240
                                                                                  123                 163
                                           58                  81
    16                  38

   2008                 2009               2010               2011                2012                2013                2014      2015                  2016         2017         2018E2)

  Launch in           FAIR-HF          FERGI-COR                            PREFER study           FIND-CKD            CONFIRM-   New EU               New ESC      Intensifying
  CH, UK,             study            study                                (fatigue)              study (ND-          HF study   onco                 guidelines   promotional
  Spain               (cardio)         (gastro)                                                    CKD)                (cardio)   guidelines           (cardio)     effort by
                                                                            New EU
                                                                                                                                                                    Daiichi
                                                                            guidelines:            Injectafer®                                         EFFECT-HF
                                                                                                                                                                    Sankyo
                                                                            nephro, cardio,        approved                                            study
                                                                            gastro, onco           in the USA                                          (cardio)

  Europe         US     ROW
MAT = Moving annual total
1) Based on Quarterly IQVIATM MIDAS® panel, GERS, Insight Health, DLI, historical data at constant exchange rate (average 2017)    2) Estimate based   on IQVIATM

© Vifor Pharma             January 2019                                                                                                                                                       7
FERINJECT®
SIGNIFICANT MARKET OPPORTUNITY REMAINS 1)
                                           Ferinject® in-market volume growth                                Ferinject® volume per capita2)
                                                                                                                                                Launch Date

                                                                                  5%           Switzerland                                    253   2008

                                                             33%                                 Australia                            107           2011

                                               47%                                            New Zealand                        51                 2012

                                                                         16%                     Sweden                     36                      2008

                                                                         16%                    Germany                     34                      2007

                                                       39%                                        Spain                 29                          2009

                                                                         16%                      France               22                           2011

                                                                   22%                              UK                 22                           2008

                                           53%                                                     Italy               22                           2012

                                                 45%                                               U.S.           12                                2013

                                                                                       0%         Japan       0                                     2019

                                                                                       0%         China       0                                     2021
1) Based   on Quarterly IQVIATM MIDAS® panel, GERS, Insight Health, Moving Annual Total (MAT) Q2 2017-18
2)   100 mg eq./1’000 population

© Vifor Pharma              January 2019                                                                                                                   8
FERINJECT®
THE BLOCKBUSTER PLAN

        Therapeutic                                     • Heart failure              Strong         • Partnering with leading
        areas with high                                 • Patient blood management   partnerships     companies
        unmet need                                      • Gastroenterology
                                                        • Nephrology

        Geographic                                      • Japan (2019)               Life cycle     • AFFIRM-AHF
        expansion                                       • China (2021)               management     • HEART-FID1)
                                                        • Key pharmerging markets

1)   Study conducted by our US partner Daiichi Sankyo

© Vifor Pharma               January 2019                                                                                       9
FERINJECT®
EXPLOIT THE POTENTIAL

           2019                               2020               2021                           2022                      2023         2024              2025

                                                                                                                                               > CHF 2 billion
           Japan launch                                                 China launch
                                                                                                                                               in-market sales
           H2 2019                                                      2021
                                                                                                                                                  potential
                AFFIRM-AHF                                 FAIR-HF2                              HEART-FID
                                                                                                                                 U.S. label
                completion                                 completion1)                          completion2)
                                                                                                                                  update
                Post-approval study                        Post-approval study                   U.S. Post-approval study

                                  Focus on cardiology, patient blood management, gastroenterology and nephrology

                                         EU guidelines*                                                                          U.S. guidelines*
                                         update based on                                                                         update based on
                                         AFFIRM AHF                                                                              HEART-FID

     *Targeted guidelines:

1)   Investigator initiated study, University of Hamburg          2)   Study conducted by our US partner Daiichi Sankyo

© Vifor Pharma                 January 2019                                                                                                                      10
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
THE RATIONALE

                                                                           55% Stake
           STRONG IRON AND PHARMA EXPERTISE

                                                           1)

                                                                CCX1401)

                                                          Avacopan1)

                                              CR8451)   Vadadustat1)

                      GLOBAL LEADER IN DIALYSIS

                                                                           45% Stake

1) Pre-commercial   products

© Vifor Pharma                 January 2019                                            11
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
SYNERGISTIC PARTNERSHIP
                                                                                                           55% Stake

               STRONG IRON AND PHARMA EXPERTISE
                              Sourcing of innovation
                          Evaluation of clinical assets
                           Acceptance of clinical risk
               Regulatory and market access expertise                                                  Focus on pharma needs of nephrology patients – Global Leader
                                                                                                            Access to patient data. Faster clinical trial execution
                                                                                                                        Faster uptake and utilisation

                       GLOBAL LEADER IN DIALYSIS
                                                                                                             Partnership technically controlled by Vifor Pharma
                             Managed care expertise
                      Patient access (>300k patients)
                             Validation of innovation
             Medications in FKC clinics1) become SoC2)
                                                                                                            45% Stake
1) Fresenius  Kidney Care (FKC): Fresenius Medical Care North America dialysis provider organization
2)   Standard of care
© Vifor Pharma               January 2019                                                                                                                             12
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
CURRENT PORTFOLIO

       ANAEMIA                                MINERAL & BONE     KIDNEY     CKD-ASSOCIATED   CARDIO-RENAL
     MANAGEMENT                                MANAGEMENT      PROTECTION   COMPLICATIONS    MANAGEMENT

                                                               Avacopan1)      CR8451)

                                                          1)
                                                                CCX1401)

    Vadadustat1)
1) Pre-commercial   products

© Vifor Pharma                 January 2019                                                                 13
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
DELIVERING INNOVATION TO NEPRHOLOGY PATIENTS

          2019                         2020                 2021        2022             2023            2024            2025

                              Rayaldee®              Avacopan      Vadadustat               > CHF 1bn
                              launch                 launch        launch                 reported sales

                    CCX140 / FSGS                      CR845                    CCX140          Additional launches in
                    Ph. II trial completion            launch                   launch          nephrology

        Avacopan / AAV                     Vadadustat
        Ph. III trial                      Ph. III trials
        completion                         completion

    CR845 / Uremic
                                         Avacopan / C3G
    Pruritus                             Ph. II trial completion
    Ph. III trial completion

© Vifor Pharma          January 2019                                                                                            14
NEPHROLOGY
NUMEROUS OPPORTUNITIES REMAIN
   CURRENT INDICATIONS                PIPELINE INDICATIONS             POTENTIAL INDICATIONS

                                                                               Hypernatremia
                                                                       Vascular calcification
                                              FSGS
            Iron deficiency                                                Polycystic kidney disease
                                    ANCA associated vasculitis
                 Anaemia                                            Kidney stones               aHUS
                                   Secondary hyperparathyroidism          β-Thalassemia renal disease
       Hyperphosphatemia
             Hyperkalemia                 Uremic pruritus          Metabolic acidosis
                                                                                    Acute kidney injury
                                               C3G
                                                                         Diabetic nephropathy
                                                                                    Fabry

© Vifor Pharma      January 2019                                                                          15
NEPHROLOGY
LEADERSHIP OF THE WHOLE NEPHROLOGY CHAIN

                 PRE CLINICAL                CLINICAL / PRE-COMMERCIAL

                 PARTNERSHIP            IN-LICENSING DEALS AND PARTNERSHIPS

                                                    Avacopan

                                                                                 DATA GENERATION
                                   CCX140
                                            CR845          Vadadustat

                                     COMMERCIAL

                 PRE DIALYSIS          DIALYSIS                TRANSPLANTATION

© Vifor Pharma      January 2019                                                                   16
VELTASSA®
OVERVIEW OF KEY FEATURES

                   Mode of action                   High safety profile
             Calcium-based, non-absorbed         Limited undesirable effects

                   52-weeks data                         RAASi enabling
                 AMETHYST-DN study                  Included in SmPC1) in Europe

                               Broad use          Room temperature storage
                            Acute & Chronic       US: 3 months / EU: 6 months

1) SmPC   = summary of product characteristics

© Vifor Pharma              January 2019                                           17
VELTASSA® U.S. RAMP-UP
KEY CONSIDERATIONS

            U.S. addressable market                            3 million hyperkalemia patients

                                                               Nephrology: impact analysis ranked #11)
                          Awareness
                                                               Cardiology: Diamond study needed to unlock the cardiology space

                     Market access                             Prescribed by 89% of nephrologists2)

                           Pricing                             Monthly gross price USD 820

               Duration of treatment                           Currently ~4-5 months

                                                               67% Medicare coverage
                  Payers’ coverage
                                                               Median out-of-pocket costs of $6 for all approved claims

1)   BrandImpact, Q1’17            2)   Relypsa data on file

© Vifor Pharma              January 2019                                                                                         18
VELTASSA®
DRIVE TO BLOCKBUSTER STATUS

        2019                     2020           2021          2022              2023           2024           2025

    European rollout                               Japan launch                                          Blockbuster
                                                   Zeria                                                    status

     AMBER                              Guideline*            DIAMOND                      Guideline*
     completion                         updates based on      completion                   updates based on
     Post-approval study                AMBER results         Post-approval study          DIAMOND results

                                                                               Label updates based on
                                                                               DIAMOND results

  *Targeted guidelines:

© Vifor Pharma    January 2019                                                                                         19
R&D INVESTMENTS
KEY CLINICAL TRIALS ONGOING

                                          PHASE 1                                PHASE 2                                PHASE 3         LIFE CYCLE MANAGEMENT

                                   Oral ferroportin
                                                                       Initiation mid-2019                                                     AFFIRM-AHF (Q4 2019)
                                     inhibitor1)
     Own
                                                                                                                                                HEART FID (2022)2)
   Products
                                                                                                                                                 AMBER (H1 2019)
                                                                                                                                                 DIAMOND (2022)

                                                                                                                   Avacopan (Q4 2019)

 In-licensed                                                                CCX140 (2020)
  Products
                                                                                                                    CR845 (H2 2019)

                                                                                                                   Vadadustat (2020)

1) Iron   overload; leveraging iron metabolism expertise   2)   Study conducted by our US partner Daiichi Sankyo

© Vifor Pharma                 January 2019                                                                                                                           20
FINANCIAL HIGHLIGHTS 1)

                        NET SALES                                                                        EBITDA                                             FERINJECT®/INJECTAFER®

                 +23.4%                                                                      +44.5%                                                              +29.3%
               CORE EPS2) (in CHF)                                                   NET DEBT (in million CHF)                                                   EQUITY RATIO

                           2.66                                                                    127.5                                                         80.0%
1) Half-year results 2018
2)   Reported earnings after minorities adjusted for amortisation of intangible assets to normalise for the significant impact from the acquisition of Relypsa

© Vifor Pharma                 January 2019                                                                                                                                          21
GUIDANCE 2018
NET SALES AND EBITDA GUIDANCE INCREASED

                 In 2018 at constant exchange rates Vifor Pharma net sales are expected to grow
                 by more than 15% and reported EBITDA by more than 25%.
                 In 2020 net sales are expected to exceed CHF 2 billion and EBITDA to reach a high triple-digit
                 level.
                 For 2018 and 2019, the dividend is expected to be at the same level as for 2017. From 2020
                 onwards, the payout ratio is targeted at 35% of net income.

© Vifor Pharma        January 2019                                                                                22
OUTLOOK 2019

                                 Ferinject® launch in Japan (H2 2019)
                                 Rayaldee® filing in Europe (H1 2019)
 MARKET ACCESS
                                 Expansion of footprint in China
                                 Partnering the Japanese rights for CCX140

 IN-LICENSING                    Completion of at least one additional bolt-on transaction during the course of 2019

                                 Veltassa®: read-out of the AMBER study (H1 2019)
                                 Veltassa®: initiation of the DIAMOND outcome study for RAASi enabling (Q1 2019)
 CLINICAL TRIALS                 Ferroportin inhibitor: initiation of phase-II study (mid-2019)
                                 Avacopan: phase III ADVOCATE study readout (Q4 2019)
                                 CR845: KALM-1 and KALM-2 study readouts (H2 2019)

© Vifor Pharma   January 2019                                                                                           23
CONTACT INFORMATION

                            Colin Bond – CFO
                            Phone:    +41 58 851 83 53
                            Email:    colin.bond@viforpharma.com

     INVESTOR RELATIONS

                            Julien Vignot – Head of Investor Relations
                            Phone:    +41 58 851 66 90
                            Email:    julien.vignot@viforpharma.com

                            Laurent de Weck – Investor Relations Manager
                            Phone:    +41 58 851 80 95
                            Email:    laurent.deweck@viforpharma.com

© Vifor Pharma   January 2019                                              24
DISCLAIMER

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as
appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-
looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to
differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude
of factors including, but not limited to, changes in demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated development. Forward-looking statements contained
in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities
will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update
or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change
in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the
Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person’s
officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors
nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this
presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-
looking statements, which speak only as of the date of this presentation.

© Vifor Pharma   January 2019                                                                                                 25
You can also read